Posted May. 3, 2012 at 9:13 a.m.

Premium Lock Charlotte firm may seek narrower use for drug to treat Parkinson's sympton

Published: 2012-05-03 09:13:23
Updated: 2012-05-03 09:13:23


If results of an ongoing phase 3 study don't support the durability of Northera's effect over time, Chelsea Therapeutics "might seek to obtain approval for Northera as an acute rather than a chronic treatment."...

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2017 MedCity. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders